{"filing":{"accession_number":"0001628280-26-049937","cik":"0002023658","ticker":"BCAX","company_name":"Bicara Therapeutics Inc.","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-23","primary_document":"bcax-20260723.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026049937/bcax-20260723.htm"},"events":[{"id":20942,"run_id":18863,"accession_number":"0001628280-26-049937","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Bicara Therapeutics appointed Jeremy Bender, Ph.D. (former CEO of Day One Biopharmaceuticals) and Christy Oliger (former SVP of Oncology at Genentech) as directors on July 28, 2026, bringing 20+ and 30+ years of biotech and biopharmaceutical experience respectively. The appointments include committee assignments and formation of a new Launch Readiness Committee to support the company's commercialization efforts for its lead program ficerafusp alfa.","company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20452,"accession_number":"0001628280-26-049937","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the resignation of Kiran Mazumdar-Shaw from the Board and the appointment of Jeremy Bender, Ph.D. and Christy Oliger as directors on July 28, 2026. While both events occur, the primary focus and substantive disclosure centers on the appointments of two new directors with significant industry experience (Bender's 20+ years in biotech strategy and Oliger's 30+ years in biopharmaceutical commercial operations), their committee assignments, and the formation of a new Launch Readiness Committee. The resignation is noted as non-contentious and the departing director is being replaced. The appointments are material to investors as they bring experienced leadership during a critical commercialization phase for the company's lead program ficerafusp alfa.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:36:45.266372+00:00","company_name":"","ticker":null,"filing_date":""},{"id":20453,"accession_number":"0001628280-26-049937","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two directors to Bicara's Board: Jeremy Bender, Ph.D., MBA (former CEO of Day One Biopharmaceuticals) and Christy Oliger (former SVP of Oncology at Genentech), both bringing substantial industry experience in biotechnology and oncology. While the filing also mentions Kiran Mazumdar-Shaw's retirement from the Board, the principal disclosed action centers on the two new appointments. Board composition changes at clinical-stage biopharmaceutical companies are material to investors assessing governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:36:45.266372+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20452,"accession_number":"0001628280-26-049937","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the resignation of Kiran Mazumdar-Shaw from the Board and the appointment of Jeremy Bender, Ph.D. and Christy Oliger as directors on July 28, 2026. While both events occur, the primary focus and substantive disclosure centers on the appointments of two new directors with significant industry experience (Bender's 20+ years in biotech strategy and Oliger's 30+ years in biopharmaceutical commercial operations), their committee assignments, and the formation of a new Launch Readiness Committee. The resignation is noted as non-contentious and the departing director is being replaced. The appointments are material to investors as they bring experienced leadership during a critical commercialization phase for the company's lead program ficerafusp alfa.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:36:45.266372+00:00","company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","filing_date":"2026-07-28"},{"id":20453,"accession_number":"0001628280-26-049937","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two directors to Bicara's Board: Jeremy Bender, Ph.D., MBA (former CEO of Day One Biopharmaceuticals) and Christy Oliger (former SVP of Oncology at Genentech), both bringing substantial industry experience in biotechnology and oncology. While the filing also mentions Kiran Mazumdar-Shaw's retirement from the Board, the principal disclosed action centers on the two new appointments. Board composition changes at clinical-stage biopharmaceutical companies are material to investors assessing governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:36:45.266372+00:00","company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","filing_date":"2026-07-28"}]}